New post-hoc analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) tablets reduced the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, regardless of starting blood sugar levels or blood sugar control early in the study. A reduction in cardiovascular death was also seen when Jardiance was added to common first and second-line diabetes medications, such as metformin or sulfonylurea. These data were presented on behalf of Boehringer Ingelheim and Eli Lilly and Company at the 53rd Annual Meeting of the European Association for the Study of Diabetes.